127 related articles for article (PubMed ID: 1930732)
1. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine.
Lenz V; Gattner HG; Sievert D; Wollmer A; Engels M; Höcker H
Biol Chem Hoppe Seyler; 1991 Jul; 372(7):495-504. PubMed ID: 1930732
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-assisted semisynthesis of shortened B26-modified insulins.
Sievert D; Gattner HG; Lenz V; Höcker H
Biomed Biochim Acta; 1991; 50(10-11):S197-200. PubMed ID: 1820045
[TBL] [Abstract][Full Text] [Related]
3. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
[TBL] [Abstract][Full Text] [Related]
4. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.
Záková L; Barth T; Jirácek J; Barthová J; Zórad S
Biochemistry; 2004 Mar; 43(8):2323-31. PubMed ID: 14979729
[TBL] [Abstract][Full Text] [Related]
5. Structure-function relationships of des-(B26-B30)-insulin.
Spoden M; Gattner HG; Zahn H; Brandenburg D
Int J Pept Protein Res; 1995; 46(3-4):221-7. PubMed ID: 8537175
[TBL] [Abstract][Full Text] [Related]
6. In vivo metabolic activity of des-(B26-B30)-insulin-B25-amide and related analogues in the rat.
Stümpel F; Hartmann H; Brandenburg D; Creutzfeldt W
Diabetes Res Clin Pract; 1990 Jul; 9(3):257-64. PubMed ID: 2226126
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of des-(B26-B30)-insulinamide and related analogues in rat hepatocyte cultures.
Hartmann H; Oberhaus K; Spahr R; Brandenburg D; Creutzfeldt W; Probst I
Diabetologia; 1989 Jul; 32(7):416-20. PubMed ID: 2680697
[TBL] [Abstract][Full Text] [Related]
8. Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins.
Cosmatos A; Ferderigos N; Katsoyannis PG
Int J Pept Protein Res; 1979; 14(5):457-71. PubMed ID: 395118
[TBL] [Abstract][Full Text] [Related]
9. Acute metabolic actions of des-(B27-B30)-insulin and related analogues in adult rats.
Hartmann H; Korf J; Ottmers U; Creutzfeldt W
Acta Diabetol; 1993; 30(2):108-14. PubMed ID: 8219258
[TBL] [Abstract][Full Text] [Related]
10. Structure-function relationships of shortened [LeuB25]insulins, semisynthetic analogues of a mutant human insulin.
Fischer WH; Saunders D; Brandenburg D; Diaconescu C; Wollmer A; Dodson G; De Meyts P; Zahn H
Biol Chem Hoppe Seyler; 1986 Sep; 367(9):999-1006. PubMed ID: 3539147
[TBL] [Abstract][Full Text] [Related]
11. Semisynthetic insulin analogues modified in positions B24, B25 and B29.
Svoboda I; Brandenburg D; Barth T; Gattner HG; Jirácek J; Velek J; Bláha I; Ubik K; Kasicka V; Pospísek J
Biol Chem Hoppe Seyler; 1994 Jun; 375(6):373-8. PubMed ID: 7980868
[TBL] [Abstract][Full Text] [Related]
12. Implications of replacing peptide bonds in the COOH-terminal B chain domain of insulin by the psi (CH2-NH) linker.
Nakagawa SH; Johansen NL; Madsen K; Schwartz TW; Tager HS
Int J Pept Protein Res; 1993 Dec; 42(6):578-84. PubMed ID: 8307689
[TBL] [Abstract][Full Text] [Related]
13. High resolution 1H-NMR studies of Des-(B26-B30)-insulin; assignment of resonances and properties of aromatic residues.
Hua QX; Chen YJ; Wang CC; Wang DC; Roberts GC
Biochim Biophys Acta; 1989 Feb; 994(2):114-20. PubMed ID: 2642711
[TBL] [Abstract][Full Text] [Related]
14. The solution structure of a superpotent B-chain-shortened single-replacement insulin analogue.
Kurapkat G; Siedentop M; Gattner HG; Hagelstein M; Brandenburg D; Grötzinger J; Wollmer A
Protein Sci; 1999 Mar; 8(3):499-508. PubMed ID: 10091652
[TBL] [Abstract][Full Text] [Related]
15. Structural determinants of ligand recognition by type I insulin-like growth factor receptors: use of semisynthetic insulin analog probes.
Cara JF; Nakagawa SH; Tager HS
Endocrinology; 1988 Jun; 122(6):2881-7. PubMed ID: 2967179
[TBL] [Abstract][Full Text] [Related]
16. The solution structure of a monomeric insulin. A two-dimensional 1H-NMR study of des-(B26-B30)-insulin in combination with distance geometry and restrained molecular dynamics.
Knegtel RM; Boelens R; Ganadu ML; Kaptein R
Eur J Biochem; 1991 Dec; 202(2):447-58. PubMed ID: 1761045
[TBL] [Abstract][Full Text] [Related]
17. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
Nakagawa SH; Tager HS
J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
[TBL] [Abstract][Full Text] [Related]
18. A shortened insulin with full in vitro potency.
Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
[TBL] [Abstract][Full Text] [Related]
19. B-chain shortening of matrix-bound insulin with pepsin, II. Preparation and properties of camel des-pentapeptide (B26-30)- and des-PheB1-des-pentapeptide (B26-30)- insulin.
Danho WO; Gattner HG; Nissen D; Zahn H
Hoppe Seylers Z Physiol Chem; 1975 Sep; 356(9):1405-12. PubMed ID: 1100508
[TBL] [Abstract][Full Text] [Related]
20. Self-association of des-(B26-B30)-insulin. The effect of Ca2+ and some other divalent cations.
Jeffrey PD
Biol Chem Hoppe Seyler; 1986 May; 367(5):363-9. PubMed ID: 3527222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
